NCT03180307 - OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

January 26, 2018

Primary Completion Date

April 16, 2020

Study Completion Date

October 16, 2020

Conditions

Ovarian Cancer

Interventions

DRUG

OTL38

0.025 mg/kg of OTL38 in 250ml dextrose 5% in water (D5W) infused intravenously over 60 minutes

DEVICE

near infrared camera imaging system

Infrared imaging used to excite OTL38 for fluorescence

PROCEDURE

laparotomy

primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery

Trial Locations (11)

University of Pennsylvania, Philadelphia

Moffitt Cancer Center, Tampa

Kettering Medical Center, Kettering

Karmanos Cancer Institutes, Detroit

Mayo Clinic-Rochester, Rochester

Washington University School of Medicine, St Louis

The Mayo Clinic - Phoenix, Phoenix

University of Arizona, Tucson

City of Hope Medical Center, Duarte

University of CA at Irvine Chao Cancer Center, Orange

Leiden University Medical Center, Leiden